Cover Image
Market Research Report

Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast 2019-2024

Published by IndustryARC Product code 422640
Published Content info
Delivery time: 2-3 business days
Back to Top
Pharmacovigilance Market: By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial); By Type of Service Providers (In House, Contract Outsourcing) & By Region-Forecast 2019-2024
Published: December 23, 2018 Content info:

Pharmacovigilance is referred to as a practice of monitoring the effects of medical drugs after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse reactions. Globally, increasing incidence rates of ADR (adverse drug reaction) which also represent a substantial burden on healthcare systems, coupled with the introduction of stringent government policies in developing nations pertaining to drug safety regulations are some key factors expected to drive the pharmacovigilance market during the period of study.

Geographically, North America dominated the pharmacovigilance market driven by strict drug safety approval regulations imposed by the U.S. FDA and other regulatory authorities coupled with increasing pressure for maintaining electronic medical records (EMR). North America was followed by Europe and Asia-Pacific as second and third largest market for the pharmacovigilance market. Asia Pacific is projected to have the fastest growth, owing to availability of large pool of educated and cost-effective labor force, the presence of favorable business environment and the implementation of government initiatives aimed at improving healthcare access in developing nations such as India and China.

This report identifies the pharmacovigilance market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the pharmacovigilance market.

This report segments the pharmacovigilance market on the basis of clinical trial phase, type of service provider and regional market as follows:

Pharmacovigilance market research report is classified on the basis of clinical trial phase. Some of the major clinical trial phases covered in this report are as follows: Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial

Pharmacovigilance market research report is classified on the basis of type of service provider. Some of the major service provider types covered in this report are as follows: In House, Contract Outsourcing

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the pharmacovigilance market. Some of the major companies' profiles in detail are as follows:

Quintiles Transnational Corporation

Accenture Plc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb

PAREXEL International Corporation

Table of Contents

Table of Contents

1. Pharmacovigilance Market - Overview

2. Executive Summary

3. Pharmacovigilance Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Pharmacovigilance Market- Forces

  • 4.1. Drivers
    • 4.1.1. Strict drug regulations in developed nations
  • 4.2. Restraints
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Pharmacovigilance Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Pharmacovigilance Market, By Clinical Trial Phase

  • 6.1. Preclinical Studies
  • 6.2. Phase I/1
  • 6.3. Phase II/2
  • 6.4. Phase III/3
  • 6.5. Phase IV/4 Trial

7. Pharmacovigilance Market, By Type of Service Provider

  • 7.1. In House
  • 7.2. Contract Outsourcing

8. Pharmacovigilance Market, By Geography

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Pharmacovigilance Market - Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 10.1. Quintiles Transnational Corporation
  • 10.2. Accenture Plc.
  • 10.3. Boehringer Ingelheim GmbH
  • 10.4. Bristol-Myers Squibb
  • 10.5. PAREXEL International Corporation
  • 10.6. Janssen Research & Development, LLC
  • 10.7. Pharmaceutical Product Development, Inc.
  • 10.8. United BioSource Corporation
  • 10.9. Synowlwedge LLC
  • 10.10. Cognizant Technology Solutions Corporation
  • 10.11. Covance Inc.
  • 10.12. ICON, Plc..

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top